Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2012

View Archived Issues

New bacterial strain targets hypoxic regions of solid tumors

Mouse model of McArdle's disease created / News in Context

Takeda reviews highlights for first quarter of fiscal 2012

Capstone Therapeutics and LipimetiX enter joint venture

Novel fatty acid synthase inhibitors designed

Scientists develop new DGAT inhibitors

New antibiotics prepared in Portugal

Novel protein kinase inhibitors disclosed

TWi Pharmaceuticals reports phase IIb results on AC-201

Study identifies role of thrombomodulin-aPC pathway in radioprotection

Research at Bioenergenix yields novel PAS-kinase inhibitors

Antibody improves glycemia in first-in-human study

Dyax presents new plasma kallikrein-binding antibodies

Recruitment begins in phase Ib/IIa Declotana study

New vaccine approved in Japan for prevention of pertussis, diphtheria, tetanus and poliomyelitis

Rexahn completes exploratory RX-3117 study

Phase II Zybrestat combination study meets safety criteria

PharmaEngine and Nanobiotix enter license and collaboration agreement for radioenhancer

HIV drug prevents GVHD and preserves immune function in bone marrow transplant recipients

Pluristem gains clearance for PLX cell study in Germany

Phase III Alzheimer's disease program discontinued

Saladax and Bristol-Myers Squibb expand collaboration

Phase III trial in NSCLC does not meet primary endpoint

Novel PI3K-delta inhibitor discovered by researchers from Cellzome

Antisense Therapeutics prepares for phase II trial in acromegaly

Novacta Biosystems completes phase I study of oral treatment for CDI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...